pre-clinical research

Advantageous Systems LLC (ADS) is a global company integrating nanotechnology, material science, and biotechnology to produce smart materials with unique functional characteristics. Applications include medical devices, therapeutics, and clean technology products. ADS produces patented water remediation and desalination technology using supramolecular chemistry and nanotechnology, and is developing a minimally-invasive point-of-care diagnostic device and novel small molecule therapeutics.

desalinationdrug deliverynanotechnologysupramolecular chemistrywater treatment

Alpha Tau Medical is a clinical-stage oncology company pioneering intratumoral alpha-emitting radiotherapeutics to address multiple solid tumor types, including those with few or no currently viable treatment options. Its Alpha DaRT® delivery systems use tiny sources containing radium-224 placed into tumors to release alpha particles that destroy cancer cells from within.

clinical trialsintratumoral alpha-emitting radiotherapy

Argenica Therapeutics Limited (ASX:AGN) is a clinical stage drug development company developing novel neuroprotective therapeutics to reduce brain damage after stroke and other acute brain injuries. Its lead candidate ARG-007, a cationic arginine-rich peptide, is based on research from The University of Western Australia and the Perron Institute for Neurological and Translational Science. ARG-007 has completed a Phase 1 clinical trial and is being tested in a Phase 2 clinical trial in acute ischaemic stroke patients in Australia.

clinical trialscommercialisation of therapeuticsdrug development

Australis is a global biopharmaceutical company developing cancer therapies, centered on its lead compound AUS_001, a naturally derived compound discovered in honeybee propolis from Kangaroo Island. Its in-house research is based at a laboratory in Simi Valley, California, staffed by PhD scientists, with third-party research performed worldwide. AUS_001 has shown pre-clinical efficacy against 24 types of cancer and has received FDA Orphan Drug Designation for malignant gliomas and Rare Pediatric Disease Designation for pediatric-type diffuse high-grade g

clinical trial developmentdrug formulationGLP toxicology studiesin vitro and in vivo studies

BioKier Inc. is an early-stage clinical-stage pharmaceutical company developing proprietary medical foods and drugs for diabetes and related disorders. Its lead product, BKR-017, is an oral capsule formulated to deliver L-glutamine to the colon to mimic the effects of bariatric-metabolic surgery and improve gut hormone secretion and regulation of glucose and lipids.

clinical trialsdrug formulationtargeted colonic delivery

RockGen Therapeutics is a start-up biotechnology pharmaceutical company developing treatments for neurodegenerative diseases. It uses cutting-edge research into central nervous system diseases to develop novel, disease-modifying medicines, with Amyotrophic Lateral Sclerosis (ALS) as its first target, and broader efforts on Alzheimer's, Parkinson's, Huntington's, and other neurodegenerative disorders. Its pre-clinical work focuses on an anti-aggregating class of drugs.

drug developmentinnovative chemistryin silico systemswet laboratory systems

CavGene Therapeutics, Inc. is a pre-clinical stage gene therapy company founded in November 2022 and headquartered in East Lansing, Michigan. It is developing proprietary AAV-based RNA interference (RNAi) therapeutics targeting specific L-type calcium channel isoforms in the brain for the treatment of neurodegenerative disease, including levodopa-induced dyskinesias in Parkinson's disease.

AAV-based RNA interference (RNAi)gene therapy

EnduRx Pharmaceuticals Inc. is a virtual, pre-clinical company developing a peptide-directed polymeric nanoparticle drug delivery platform and therapeutics for hard-to-treat solid tumors and selected other indications. Its candidates are designed to achieve tumor-specific delivery of active pharmaceutical ingredients while avoiding healthy tissue. The company is led by experienced life science executives and scientists and utilizes resources across the US, with a corporate office in Tucson, AZ.

drug delivery platform developmentnanoparticle therapeutics

FluGen, Inc. is developing a more effective vaccine in the fight against influenza and respiratory disease. Its M2SR Vaccine Platform is a clinically-tested vaccine candidate addressing unmet needs in flu prevention, including consistent efficacy, annual virus drift, and shedding. The flagship candidate M2SR is an intranasal, supra-seasonal flu vaccine that stimulates mucosal, humoral, and cellular immunity. Long-term R&D plans include potential application against SARS-CoV-2 (COVID-19) and other respiratory diseases such as RSV.

clinical trialsintranasal vaccinevaccine development